Dapagliflozin and heart-pump fit after off-pump bypass
Official title: Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Artery Bypass Grafting: a Prospective Single-Center Study
Run by Pyatigorsk City Clinical Hospital Number 1 · NCT07601867 · Data updated 2026-11-12
This study tests whether 10 mg/day of dapagliflozin helps the right heart work better with the lungs after OPCAB in adults with reduced heart pumping function.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 72 (estimated) |
| Sponsor | Pyatigorsk City Clinical Hospital Number 1 Government |
| Locations | 1 site (Pyatigorsk, Stavropol Kray) |
| Status | Recruiting |
| Started | July 1, 2026 |
| Main results expected | May 1, 2028 |
| Study ends | July 1, 2028 |
| Registry record updated | June 17, 2026 |
| Trial ID | NCT07601867 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with prior OPCAB and LVEF <50% who can undergo serial echocardiography and consent.
✕Probably not a fit
Patients without accessible echo data or with conditions precluding SGLT2 use may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective, single-center observational study follows adults with LVEF under 50% who have undergone off-pump CABG. Echocardiography is done before surgery, at 1 month after surgery before starting dapagliflozin, and again at 7 months after surgery after 6 months of treatment. The main goal is to see if the TAPSE/PASP ratio improves with therapy; secondary goals include changes in PASP, PVR, RV function, LV function, NT-proBNP, and quality of life scores. The study seeks mechanistic insight on how SGLT2 inhibition may influence right heart–pulmonary circulation after OPCAB.
Why it matters
Potential benefit: If successful, patients may experience improved right heart function and symptom burden after OPCAB.
How similar studies have gone: Prior work suggests SGLT2 inhibitors can improve heart failure markers; the specific post-OPCAB right heart coupling approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Elective isolated off-pump coronary artery bypass grafting (OPCAB) * Left ventricular ejection fraction (LVEF) \< 50% documented on pre-operative echocardiography * Written informed consent Exclusion Criteria: * Concomitant valve surgery * Emergency or urgent CABG * Conversion to on-pump during surgery * Perioperative myocardial infarction (as defined by the Fourth Universal Definition of MI) * Cardiogenic shock * More than moderate valvular heart disease * Persistent atrial fibrillation or atrial flutter at the time of echocardiographic examination) * Previous CABG or any prior cardiac surgery * Severe chronic kidney disease (eGFR \< 25 mL/min/1.73 m²) * Contraindication to SGLT2 inhibitors * Inability to obtain adequate echocardiographic windows * Pregnancy or breastfeeding
Where it's running
-
Pyatigorsk City Clinical Hospital Number 1
Pyatigorsk, Stavropol Kray, Russia Recruiting
Study contacts
- Principal investigator: Samson S. Badalyan, MD, PhD — Pyatigorsk City Clinical Hospital Number 1
- Study coordinator: Samson S. Badalyan, MD, PhD
- Email: sambadalyan@mail.ru
- Phone: +79614972949
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
Comparing Aortix Device to Diuretics for Acute Heart Failure
This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.
-
Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS
Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.
-
Tailored digital support to cut sedentary time in long-term cardiac rehab
In adults in a long-term cardiac rehabilitation program, this study tests whether a personalized behavioural program with digital tools can reduce daily sitting time.
-
NT-proBNP–guided heart failure screening for people 65+ in rural China
This study tests whether using NT-proBNP blood tests to guide heart failure screening in adults 65 and older in rural China can find unrecognized heart problems more effectively than symptom-based screening.
-
Voice-based detection of heart failure deterioration using Noah Labs Vox
This study tests whether a voice-analysis app can flag worsening heart failure in adults by comparing its alerts to standard weight-based monitoring.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.